(Q38921009)

7 September 2017

title

Sorafenib reverses resistance of gastric cancer to treatment by cisplatin through down-regulating MDR1 expression (English)

1 reference

7 September 2017

1 reference

Yi-Sheng Huang

1

1 reference

7 September 2017

Zhi Xue

series ordinal

2

1 reference

7 September 2017

Hua Zhang

series ordinal

3

1 reference

7 September 2017

publication date

13 January 2015

1 reference

7 September 2017

1 reference

7 September 2017

volume

32

1 reference

7 September 2017

issue

2

1 reference

7 September 2017

page(s)

470

1 reference

7 September 2017

cites work

Global cancer statistics

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0470-1

The regulation of extracellular signal-regulated kinase (ERK) in mammalian cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0470-1

Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0470-1

Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0470-1

PERK-dependent regulation of ceramide synthase 6 and thioredoxin play a key role in mda-7/IL-24-induced killing of primary human glioblastoma multiforme cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0470-1

OSU-03012 stimulates PKR-like endoplasmic reticulum-dependent increases in 70-kDa heat shock protein expression, attenuating its lethal actions in transformed cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0470-1

Sorafenib and vorinostat kill colon cancer cells by CD95-dependent and -independent mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0470-1

BCL-2 family inhibitors enhance histone deacetylase inhibitor and sorafenib lethality via autophagy and overcome blockade of the extrinsic pathway to facilitate killing

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0470-1

Sorafenib Activates CD95 and Promotes Autophagy and Cell Death via Src Family Kinases in Gastrointestinal Tumor Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0470-1

Targeting multidrug resistance in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0470-1

New use for an old drug: inhibiting ABCG2 with sorafenib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0470-1

Interaction of the multikinase inhibitors sorafenib and sunitinib with solute carriers and ATP-binding cassette transporters

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0470-1

Tyrosine kinase inhibitors gefitinib, lapatinib and sorafenib induce rapid functional alterations in breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0470-1

Reversing multidrug resistance by RNA interference through the suppression of MDR1 gene in human hepatoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0470-1

Associations of polymorphisms in DNA repair genes and MDR1 gene with chemotherapy response and survival of non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0470-1

HIF-1α inhibition reverses multidrug resistance in colon cancer cells via downregulation of MDR1/P-glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0470-1

Enhanced exposure of phosphatidylserine in human gastric carcinoma cells overexpressing the half-size ABC transporter BCRP (ABCG2).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0470-1

Phase II study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma: ECOG 5203.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0470-1

Phase II study of sunitinib as second-line treatment for advanced gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0470-1

An open-label, multicentre biomarker-oriented AIO phase II trial of sunitinib for patients with chemo-refractory advanced gastric cancer

21 January 2018

1 reference

12 December 2020

Expression of multidrug-resistance-related proteins P-glycoprotein, glutathione-S-transferases, topoisomerase-II and lung resistance protein in primary gastric cardiac adenocarcinoma

1 reference

12 December 2020

Expression of multidrug resistance-related markers in gastric cancer.

1 reference

12 December 2020

Phase I dose-finding study of sorafenib in combination with capecitabine and cisplatin as a first-line treatment in patients with advanced gastric cancer

1 reference

12 December 2020

[Sorafenib reverses multidrug resistance of hepatoma cells in vitro].

1 reference

12 December 2020

Overexpression of sorcin results in multidrug resistance in gastric cancer cells with up-regulation of P-gp

1 reference

12 December 2020

10.1007/S12032-014-0470-1

Identifiers

DOI

1 reference

Dimensions Publication ID

7 September 2017

1002579537

0 references

1 reference